Table 2.
Any fusion | 5′ Fusion partner | 3′ Fusion partner | |
---|---|---|---|
≥ 1 Tumor | 802 | 691 | 640 |
≥ 1 Tumor and in Mitelman | 320 (40%) | 192 (28%) | 162 (25%) |
Recurrent (≥ 3 tumors) | 514 | 426 | 380 |
Recurrent and in Mitelman | 222 (43%) | 137 (32%) | 94 (25%) |
Recurrent in both our data and Mitelman | 9 (2%) | 4 (1%) | 4 (1%) |
Number of miRNA precursors encoded in host genes with fusion transcripts with the corresponding percentage previously reported in breast cancer in the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer in parenthesis. 5ʹ or 3ʹ fusion partner refers to the position of the miRNA host gene and the column “any fusion” combines all precursors present in 5ʹ and/or 3ʹ fusion partner genes. Recurrent fusions were defined as occurring in at least three tumors with the host gene in the same position in our data